DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Marginal Zone Lymphoma Emerging drugs, the Marginal Zone Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Marginal Zone Lymphoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Marginal Zone Lymphoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Marginal Zone Lymphoma clinical trials studies, Marginal Zone Lymphoma NDA approvals (if any), and product development activities comprising the technology, PI3K inhibitors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from Marginal Zone Lymphoma Pipeline Insight Report
To explore more information on the latest breakthroughs in the Marginal Zone Lymphoma Pipeline treatment landscape of the report, click here @ Marginal Zone Lymphoma Pipeline Outlook
Marginal Zone Lymphoma Overview
Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin’s lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. EMZL can originate at virtually any extranodal site and arises in organs that normally lack lymphoid tissue (eg, stomach, intestine, thyroid, lung, and skin).
Recent Breakthroughs of Marginal Zone Lymphoma Treatment Landscape
For further information, refer to the detailed Marginal Zone Lymphoma Unmet Needs, Marginal Zone Lymphoma Latest Drugs Launch News, and Breakthroughs, click here for Marginal Zone Lymphoma Ongoing Clinical Trial Analysis
Marginal Zone Lymphoma Emerging Drugs Profile
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib’s pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
Marginal Zone Lymphoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Marginal Zone Lymphoma. The companies which have their Marginal Zone Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Incyte Corporation.
Request a sample and discover the recent advances in Marginal Zone Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Marginal Zone Lymphoma Treatment Landscape Analysis
Scope of the Marginal Zone Lymphoma Pipeline Report
Dive deep into rich insights for drugs for Marginal Zone Lymphoma Market Drivers and Market Barriers, click here @ Marginal Zone Lymphoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Marginal Zone Lymphoma Mergers and acquisitions, Marginal Zone Lymphoma Licensing Activities @ Marginal Zone Lymphoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/